GuidelineMMWR. Morbidity and mortality weekly report2017
Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine - Advisory Committee on Immunization Practices, 2016.
Guideline in MMWR. Morbidity and mortality weekly report, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2020Guideline
- Outbreaks of meningococcal meningitis in non-African countries over the last 50 years: a systematic review.Journal of global health · 2019Pooled it
- Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2019.MMWR. Morbidity and mortality weekly report · 2019Guideline
- Public Health Impact and Cost-Effectiveness of Revising the Adolescent Meningococcal Vaccine Schedule in the United States.PharmacoEconomics · 2026Article
- Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States.PharmacoEconomics · 2025Article
- Meningococcal serogroup B vaccination series initiation in the United States: A real-world claims data analysis.Human vaccines & immunotherapeutics · 2023Article
- Estimating the population level impact of a gonococcal vaccine candidate: Predictions from a simple mathematical model.Vaccine · 2022Article
- Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review.Infectious diseases and therapy · 2022Review
- Meningococcal Disease in Pediatric Age: A Focus on Epidemiology and Prevention.International journal of environmental research and public health · 2022Article
- Outcomes from the Use of Targeted Interventions to Increase Meningococcal Vaccination Rates in a Pediatric Clinic.Journal of community health · 2022Article
- Comprehensive Overview of Vaccination during Pregnancy in Europe.Journal of personalized medicine · 2021Review
- Meningococcal disease and vaccination in college students.Human vaccines & immunotherapeutics · 2021Review
- Increasing awareness and uptake of the MenB vaccine on a large university campus.Human vaccines & immunotherapeutics · 2021Article
- Perceptions and Knowledge About the MenB Vaccine Among Parents of High School Students.Journal of community health · 2021Article
- Article
- Immunizations in Chronic Kidney Disease and Kidney Transplantation.Current treatment options in infectious diseases · 2021Review
- Preventing infections in children and adults with asplenia.Hematology. American Society of Hematology. Education Program · 2020Article
- Safety Surveillance of Bivalent Meningococcal Group B Vaccine, Vaccine Adverse Event Reporting System, 2014-2018.Open forum infectious diseases · 2020Article
- Parental awareness and utilization of meningococcal serogroup B vaccines in the United States.BMC public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two serogroup B meningococcal (MenB) vaccines are currently licensed for use in persons aged 10-25 years in the United States. The two vaccines are MenB-FHbp (Trumenba, Pfizer, Inc.) (1) and MenB-4C (Bexsero, GlaxoSmithKline Biologicals, Inc.) (2). In February 2015, the Advisory Committee on Immunization Practices (ACIP) recommended use of MenB vaccines among certain groups of persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease* (Category A) (3), and in June 2015, ACIP recommended that adolescents and young adults aged 16-23 years may be vaccinated with MenB vaccines to provide short-term protection against most strains of serogroup B meningococcal disease (Category B
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.